(24/7 MARKET NEWS) – Akero Therapeutics, Inc. (Nasdaq: AKRO) is trading higher, after releasing topline data from HARMONY’s 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).
The clinical-stage company is trading at $22.93, up $10.66 (+86.88%), on 9.09 million premarket shares, after closing yesterday at $12.27, $0.56 (+4.78%), on 678,845 shares.
Its 52-week range is $7.52 to $26.98.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.